Relay Therapeutics, Inc. RLAY Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Relay Therapeutics, Inc. (RLAY) reported accretion (amortization) of discounts and premiums, investments of $782K in Q1 2026.
- How has Relay Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Relay Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 51.0% year-over-year, from $1.6M to $782K.
- What is the long-term trend for Relay Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Relay Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 34.1% compound annual growth rate (CAGR), from -$2.05M to $4.95M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Reflects the non-cash adjustment to the carrying value of investment securities to account for the difference between the purchase price and the face value over the life of the instrument. This adjustment aligns the interest income recognized with the effective yield of the investment portfolio. It provides insight into the underlying yield characteristics of the company's cash and investment holdings.